Bateman Horne Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
1997
NCT00215813
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Bateman Horne Center | LUCINDA BATEMAN, MD

Active Ingredients

Drugs in Phase 3 Trials (1)

rintatolimod (1 trial)

Drugs in Phase 2 Trials (1)

ct38 (1 trial)

Drugs in Other Trials (3)

hemp powder (1 trial)

oryza sativa (1 trial)

oxaloacetate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Encephalomyelitis (Phase 2)

Fatigue (Phase 3)

Fatigue Syndrome, Chronic (Phase 3)

Myalgia (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5